Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06981377

PRostate Cancer Plasma Integrative Multi-modal Evaluation

Development of the PRIME Test for the Identification of Prostate Cancer Patients' Biomarkers Through Non-invasive Liquid Biopsies

Status
Recruiting
Phase
Study type
Observational
Enrollment
800 (estimated)
Sponsor
Santa Chiara Hospital · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials and/or clinical settings. In order to maximise the utility of liquid biopsies for advanced PCa, PRIME is focused on the development of novel computational and sequencing approaches that integrate multiple information from plasma circulating elements: i) cell free DNA (cfDNA) gene mutation data with accurate quantitation of cfDNA structural genomic changes, ii) cfDNA genomic profiling with cfDNA methylation status, and iii) the information provided by extracellular vesicles (EVs) and EV-associated cargo (including DNA, RNA and proteins).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTAnalysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)Plasma and buffy coat samples are shipped from the recruiting clinical sites to the lab of Professor Francesca Demichelis at the University of Trento (UniTN). At UniTN, samples are stored in dedicated freezers with restricted access and subsequently used as follows: * the plasma is used for the isolation of cell free DNA and extracellular vesicles (EVs); * the buffy coat is used for the extraction of genomic DNA. Nucleic acids sequencing library preparations and all downstream omics analyses are performed by Prof. Demichelis team.

Timeline

Start date
2019-05-07
Primary completion
2027-01-31
Completion
2027-01-31
First posted
2025-05-20
Last updated
2025-05-20

Locations

4 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT06981377. Inclusion in this directory is not an endorsement.